In Asia, a substantial number of patients suffer from neuropsychiatric disorders, and the prevalence of mental health problems, such as Schizophrenia, depression, suicide, alcohol and substance abuse, and dementia, is rapidly increasing. To implement measures against these disorders, the Asian College of Neuropsychopharmacology (AsCNP) was founded in 2008. The mission of AsCNP is to encourage research, facilitate the communication of ideas in convergent disciplines of neuropsychopharmacology in Asia, develop new pharmacotherapies for the treatment for psychiatric and neurological disorders, provide education and training opportunities, and empower patients and their families with professional knowledge.
The AsCNP congress is regularly held every 2 years. Five congresses have been held to date: Kyoto, Japan (2009), Seoul, Korea (2011), Beijing, China (2013), Taipei, Taiwan (2015), and Bali, Indonesia (2017). All of these congresses were very successful, with fruitful discussions and communication under the leadership of former AsCNP Presidents. In 2019, AsCNP will hold two congresses: the 1st AsCNP-ASEAN International Neuropsychopharmacology Congress in Yogyakarta, Indonesia (February 28 to March 2) and the regular AsCNP Congress in Fukuoka, Japan (October 11-13). In 2021, the regular AsCNP congress will be held in Singapore.
AsCNP has society-based and individual-based membership systems. Currently, AsCNP has 8 society members and 18 individual members in 13 countries/regions. AsCNP currently has more than 2600 members.
We welcome neuropsychopharmacologists, psychiatrists, and neurologists, as either individual or society members, in Asia and other regions to join AsCNP and engage in its activities.
AsCNP President (2019, 2020)